Assenagon Asset Management S.A. Makes New $102,000 Investment in Ovid Therapeutics Inc. (NASDAQ:OVID)

Assenagon Asset Management S.A. acquired a new stake in Ovid Therapeutics Inc. (NASDAQ:OVID) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 86,289 shares of the company’s stock, valued at approximately $102,000. Assenagon Asset Management S.A. owned 0.12% of Ovid Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of OVID. DCF Advisers LLC raised its position in Ovid Therapeutics by 111.6% during the second quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock valued at $32,000 after acquiring an additional 22,020 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Ovid Therapeutics by 22.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock valued at $54,000 after purchasing an additional 3,145 shares during the period. BNP Paribas Financial Markets boosted its holdings in Ovid Therapeutics by 74.7% during the first quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock worth $98,000 after buying an additional 13,756 shares in the last quarter. FFT Wealth Management LLC grew its position in Ovid Therapeutics by 18.2% during the second quarter. FFT Wealth Management LLC now owns 489,552 shares of the company’s stock valued at $377,000 after buying an additional 75,530 shares during the period. Finally, Empowered Funds LLC increased its holdings in Ovid Therapeutics by 8.1% in the first quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock valued at $391,000 after buying an additional 9,625 shares in the last quarter. Hedge funds and other institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Trading Up 3.5 %

OVID stock opened at $1.18 on Tuesday. Ovid Therapeutics Inc. has a 12-month low of $0.68 and a 12-month high of $4.10. The business’s 50-day moving average is $1.15 and its 200 day moving average is $1.64. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 0.16. The stock has a market cap of $83.74 million, a price-to-earnings ratio of -2.74 and a beta of 0.41.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.34. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.14 million. Ovid Therapeutics had a negative net margin of 5,237.15% and a negative return on equity of 33.40%. On average, sell-side analysts anticipate that Ovid Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Analyst Ratings Changes

OVID has been the topic of several recent analyst reports. William Blair raised shares of Ovid Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a report on Monday, September 30th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Ovid Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $4.04.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.